WT-Y18

WT-Y18 is a small molecule drug candidate currently in the preclinical stage of development by Hangzhou Westan Pharmaceutical Technology. It is being investigated for its potential applications in tumor immunology, a field focused on modulating the immune system to recognize and attack cancer cells. The drug is currently undergoing druggability optimization to refine its pharmacological profile, including its absorption, distribution, metabolism, and excretion (ADME) properties, in preparation for potential clinical trials. As a small molecule, WT-Y18 may offer advantages such as oral bioavailability and the ability to penetrate the tumor microenvironment more effectively than larger biologic therapies.